Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors

Journal of Clinical Investigation

Volumn 127, Issue 6, 2017, Pages 2176-2191

  Smith, Tyrel T ^a   Moffett, Howell F ^a   Stephan, Sirkka B ^a   Opel, Cary F ^b,c,f   Dumigan, Amy G ^a,g   Jiang, Xiuyun ^d   Pillarisetty, Venu G ^d   Pillai, Smitha P S ^a   Wittrup, K Dane ^b,c   Stephan, Matthias T ^a,e  

^a Fred Hutchinson Cancer Research Center   (United States)

^b Massachusetts Institute of Technology   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f Gilead Sciences   (United States)

^g QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOPOLYMER; CHIMERIC ANTIGEN RECEPTOR; CYCLIC DI GMP; CYCLIC GMP; MESOPOROUS SILICA NANOPARTICLE; PROTEIN; STIMULATOR OF INTERFERON GENES PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIS(3',5')-CYCLIC DIGUANYLIC ACID; DRUG CARRIER; MEMBRANE PROTEIN; MPYS PROTEIN, MOUSE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CELL ENGINEERING; CELL THERAPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; IMPLANT DELIVERY DEVICE; LYMPHOCYTE MIGRATION; MELANOMA; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; SOLID MALIGNANT NEOPLASM; T LYMPHOCYTE; TISSUE SCAFFOLD; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ANTIGEN PRESENTING CELL; C57BL MOUSE; CANCER TRANSPLANTATION; CARCINOMA, PANCREATIC DUCTAL; IMMUNOLOGY; IMPLANT; MELANOMA, EXPERIMENTAL; PANCREATIC NEOPLASMS; PHYSIOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTINEOPLASTIC AGENTS; BIOPOLYMERS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CYCLIC GMP; DRUG CARRIERS; FEMALE; IMPLANTS, EXPERIMENTAL; MELANOMA, EXPERIMENTAL; MEMBRANE PROTEINS; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; T-LYMPHOCYTES;

EID: 85020211893     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI87624     Document Type: Article

References (55)

1. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480-489.
2. Sheikh NA, et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother. 2013;62(1):137-147.
3. Kantoff PW, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviralbased PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(7):1099-1105.
4. Amato RJ, Stepankiw M. Clinical Efficacy of Tro-Vax in the Treatment of Progressive Castrationresistant Prostate Cancer. Clin Med Insights Oncol. 2012;6:67-73.
5. Madan RA, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(5):501-508.
6. Barber GN. STING-dependent cytosolic DNA sensing pathways. Trends Immunol. 2014;35(2):88-93.
7. Fu J, et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med. 2015;7(283):283ra52.
8. Corrales L, et al. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015;11(7):1018-1030.
9. Harrison LI, Astry C, Kumar S, Yunis C. Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans. J Clin Pharmacol. 2007;47(8):962-969.
10. Walder P, et al. Pharmacokinetic profile of the immunomodulating compound adamantylamide dipeptide (AdDP), a muramyl dipeptide deriva-tive in mice. Immunopharmacol Immunotoxicol. 1991;13(1-2):101-119.
11. Kulkarni RR, et al. Activation of the RIG-I pathway during influenza vaccination enhances the germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity. J Virol. 2014;88(24):13990-14001.
12. Hanson MC, et al. Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants. J Clin Invest. 2015;125(6):2532-2546.
13. Gray PM, et al. Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities. Cell Immunol. 2012;278(1-2):113-119.
14. Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388-398.
15. Barrett DM, Grupp SA, June CH. Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street. J Immunol. 2015;195(3):755-761.
16. Grupp SA, et al. Chimeric antigen receptormodified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-1518.
17. Brentjens RJ, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.
18. Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity. 2013;39(1):61-73.
19. John LB, Kershaw MH, Darcy PK. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology. 2013;2(10):e26286.
20. Johnson DB, et al. Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer Immunol Res. 2013;1(6):373-377.
21. Läubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer. 2015;3:11.
22. Postow MA. Managing immune checkpointblocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015;76-83.
23. Parkhurst MR, et al. T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. Mol Ther. 2011;19(3):620-626.
24. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843-851.
25. Stephan SB, Taber AM, Jileaeva I, Pegues EP, Sentman CL, Stephan MT. Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat Biotechnol. 2015;33(1):97-101.
26. Hingorani SR, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7(5):469-483.
27. Sentman CL, Meehan KR. NKG2D CARs as cell therapy for cancer. Cancer J. 2014;20(2):156-159.
28. Baldwin AD, Kiick KL. Polysaccharide-modified synthetic polymeric biomaterials. Biopolymers. 2010;94(1):128-140.
29. Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol. 2005;5(6):472-484.
30. Fox JG, Barthold S, Davisson M, Newcomer CE, Quimby FW, Smith A, eds. The Mouse in Biomedical Research, Volume 3, Second Edition: Normative Biology, Husbandry, and Models. Cambridge, MA: Academica Press: 2007.
31. Ghanem G, Fabrice J. Tyrosinase related protein 1 (TYRP1/gp75) in human cutaneous melanoma. Mol Oncol. 2011;5(2):150-155.
32. Boross P, et al. Anti-tumor activity of human IgG1 anti-gp75 TA99 mAb against B16F10 melanoma in human FcgammaRI transgenic mice. Immunol Lett. 2014;160(2):151-157.
33. Albanesi M, et al. Cutting edge: FcγRIII (CD16) and FcγRI (CD64) are responsible for antiglycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma. J Immunol. 2012;189(12):5513-5517.
34. Bolander A, et al. The protein expression of TRP-1 and galectin-1 in cutaneous malignant melanomas. Cancer Genomics Proteomics. 2008;5(6):293-300.
35. Clavreul A, et al. Autologous tumor cell vaccination plus infusion of GM-CSF by a programmable pump in the treatment of recurrent malignant gliomas. J Clin Neurosci. 2010;17(7):842-848.
36. Muragaki Y, et al. Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma. Clinical article. J Neurosurg. 2011;115(2):248-255.
37. Zhou F, et al. InCVAX- A novel strategy for treatment of late-stage, metastatic cancers through photoimmunotherapy induced tumor-specific immunity. Cancer Lett. 2015;359(2):169-177.
38. Bencherif SA, et al. Injectable cryogel-based whole-cell cancer vaccines. Nat Commun. 2015;6:7556.
39. Kim J, et al. Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy. Nat Biotechnol. 2015;33(1):64-72.
40. Otsubo D, et al. Early-phase Treatment by Lowdose 5-Fluorouracil or Primary Tumor Resection Inhibits MDSC-mediated Lung Metastasis Formation. Anticancer Res. 2015;35(8):4425-4431.
41. Gang AO, et al. 5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies. Blood Cancer J. 2014;4:e197.
42. Dear AE. Epigenetic Modulators and the New Immunotherapies. N Engl J Med. 2016;374(7):684-686.
43. Héninger E, Krueger TE, Lang JM. Augmenting antitumor immune responses with epigenetic modifying agents. Front Immunol. 2015;6:29.
44. Draper LM, et al. Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6. Clin Cancer Res. 2015;21(19):4431-4439.
45. Robbins PF, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1- reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21(5):1019-1027.
46. Parkhurst MR, et al. Isolation of T cell receptors specifically reactive with mutated tumor associated antigens from tumor infiltrating lymphocytes based on CD137 expression [published online ahead of print November 8, 2016]. Clin Cancer Res. https://doi.org/10.1158/1078-0432. CCR-16-2680.
47. Thor Straten P, Garrido F. Targetless T cells in cancer immunotherapy. J Immunother Cancer. 2016;4:23.
48. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. 2013;501(7467):328-337.
49. Zhang T, Lemoi BA, Sentman CL. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood. 2005;106(5):1544-1551.
50. Dobrenkov K, et al. Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging. J Nucl Med. 2008;49(7):1162-1170.
51. Kwong B, Gai SA, Elkhader J, Wittrup KD, Irvine DJ. Localized immunotherapy via liposomeanchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. Cancer Res. 2013;73(5):1547-1558.
52. Boontheekul T, Kong HJ, Mooney DJ. Controlling alginate gel degradation utilizing partial oxidation and bimodal molecular weight distribution. Biomaterials. 2005;26(15):2455-2465.
53. Wojtowicz AM, et al. Coating of biomaterial scaffolds with the collagen-mimetic peptide GFOGER for bone defect repair. Biomaterials. 2010;31(9):2574-2582.
54. Rowley JA, Mooney DJ. Alginate type and RGD density control myoblast phenotype. J Biomed Mater Res. 2002;60(2):217-223.
55. Erskine CL, Henle AM, Knutson KL. Determining optimal cytotoxic activity of human Her2neu specific CD8 T cells by comparing the Cr51 release assay to the xCELLigence system. J Vis Exp. 2012;(66):e3683.